CN115698082A - 抗聚糖抗体及其用途 - Google Patents

抗聚糖抗体及其用途 Download PDF

Info

Publication number
CN115698082A
CN115698082A CN202180021642.8A CN202180021642A CN115698082A CN 115698082 A CN115698082 A CN 115698082A CN 202180021642 A CN202180021642 A CN 202180021642A CN 115698082 A CN115698082 A CN 115698082A
Authority
CN
China
Prior art keywords
antibody
sequence
seq
binding portion
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180021642.8A
Other languages
English (en)
Chinese (zh)
Inventor
L·普雷斯塔
T·梁
J·程
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ptm Pharmaceutical Co ltd
Original Assignee
Ptm Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptm Pharmaceutical Co ltd filed Critical Ptm Pharmaceutical Co ltd
Publication of CN115698082A publication Critical patent/CN115698082A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180021642.8A 2020-03-17 2021-03-16 抗聚糖抗体及其用途 Pending CN115698082A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062990927P 2020-03-17 2020-03-17
US62/990,927 2020-03-17
US202063037374P 2020-06-10 2020-06-10
US63/037,374 2020-06-10
US202063074956P 2020-09-04 2020-09-04
US63/074,956 2020-09-04
PCT/US2021/022627 WO2021188591A1 (en) 2020-03-17 2021-03-16 Anti-glycan antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CN115698082A true CN115698082A (zh) 2023-02-03

Family

ID=75581605

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180021642.8A Pending CN115698082A (zh) 2020-03-17 2021-03-16 抗聚糖抗体及其用途

Country Status (8)

Country Link
US (3) US11230608B2 (https=)
EP (1) EP4121460A1 (https=)
JP (2) JP2023518228A (https=)
KR (1) KR20220155333A (https=)
CN (1) CN115698082A (https=)
AU (1) AU2021237566A1 (https=)
CA (1) CA3170434A1 (https=)
WO (1) WO2021188591A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023133452A1 (en) * 2022-01-06 2023-07-13 PTM Therapeutics, Inc. Methods of treating solid tumors and compositions thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2013078425A1 (en) * 2011-11-22 2013-05-30 University Of Maryland, Baltimore Lambodies with high affinity and selectivity for glycans and uses therefor

Also Published As

Publication number Publication date
US20220340683A1 (en) 2022-10-27
US20210292432A1 (en) 2021-09-23
KR20220155333A (ko) 2022-11-22
JP2023518228A (ja) 2023-04-28
WO2021188591A1 (en) 2021-09-23
AU2021237566A1 (en) 2022-09-29
CA3170434A1 (en) 2021-09-23
EP4121460A1 (en) 2023-01-25
US11230608B2 (en) 2022-01-25
US20250034276A1 (en) 2025-01-30
JP2026031937A (ja) 2026-02-25

Similar Documents

Publication Publication Date Title
CN105916519B (zh) 抗Siglec-8抗体及其使用方法
KR102663440B1 (ko) 인간화된 항-ccr7 리셉터 항체
WO2019024911A1 (zh) B7h3抗体-药物偶联物及其医药用途
BR112019019111A2 (pt) anticorpo de b7-h3, seu fragmento de ligação ao antígeno e seu uso médico
TWI745670B (zh) 抗cd27抗體、其抗原結合片段及其醫藥用途
JP7098854B2 (ja) 自己免疫疾患およびがんを治療するための抗ｃｘｃｌ１３抗体
EP3632932A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
JP2021080289A (ja) 線維性疾患を処置するための方法および組成物
BR112020010536A2 (pt) molécula de fusão, proteína e célula isoladas, composição, e, método para tratar um câncer
TWI902681B (zh) 抗ｃｄ７９ｂ抗體、其抗原結合片段及其醫藥用途
JP2024500920A (ja) 抗ｉｌ１ｒａｐ抗体
BR112019022957A2 (pt) métodos e composições para tratamento de distúrbios gastrointestinais inflamatórios
MX2010011309A (es) Inhibidores de gm-csf e il-17 para terapia.
CN112094349A (zh) 靶向于白介素36r的抗体及其制备方法和应用
WO2022228183A1 (zh) 抗siglec15抗体及其制备方法和用途
TW202426498A (zh) Ccr8抗體之醫藥用途及給藥計劃
JP2026031937A (ja) 抗グリカン抗体及びそれらの使用
WO2020228604A1 (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
WO2021213245A1 (zh) 抗体或其抗原结合片段、其制备方法及医药用途
WO2021218895A1 (zh) 针对PD-1和TGF-β的双功能蛋白
CN118562002A (zh) 一种抗人Siglec-9微纳抗体及其应用
WO2019238074A1 (zh) 一种高亲和力高生物活性的lag-3抗体及其应用
WO2025042888A1 (en) Methods of treating digestive diseases and compositions thereof
US20240190955A1 (en) Composition comprising an ige antibody
US11912772B2 (en) Anti-galectin-9 antibody and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination